EDGAR Filing Documents for 0001564590-17-016028

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:

SEC Accession No. 0001564590-17-016028

Filing Date

2017-08-07

Accepted

2017-08-07 16:34:41

Documents

Period of Report

2017-06-30

Document Format Files

Seq	Description	Document	Type	Size
1	10-Q	atra-10q_20170630.htm	10-Q	1908493
2	EX-10.1	atra-ex101_8.htm	EX-10.1	103002
3	EX-10.2	atra-ex102_159.htm	EX-10.2	92056
4	EX-10.3	atra-ex103_160.htm	EX-10.3	76508
5	EX-31.1	atra-ex311_7.htm	EX-31.1	14989
6	EX-31.2	atra-ex312_9.htm	EX-31.2	15111
7	EX-32.1	atra-ex321_6.htm	EX-32.1	7725
	Complete submission text file	0001564590-17-016028.txt		6004812

Data Files

Seq	Description	Document	Type	Size
8	XBRL INSTANCE DOCUMENT	atra-20170630.xml	EX-101.INS	1190575
9	XBRL TAXONOMY EXTENSION SCHEMA	atra-20170630.xsd	EX-101.SCH	34539
10	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE	atra-20170630_cal.xml	EX-101.CAL	33159
11	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE	atra-20170630_def.xml	EX-101.DEF	110324
12	XBRL TAXONOMY EXTENSION LABEL LINKBASE	atra-20170630_lab.xml	EX-101.LAB	306749
13	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	atra-20170630_pre.xml	EX-101.PRE	221123

Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080

Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930

Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)